The Nationwide Pharmaceutical Pricing Authority (NPPA) has introduced a rise within the costs of over 900 important medication, as much as 1.74 per cent, from April 1. The checklist contains medicines for important infections, coronary heart illnesses, and diabetes.
Drug producers might improve the utmost retail costs of those formulations primarily based on this WPI, and no prior approval of the Centre is critical. (Consultant picture)(Unsplash)
“Further, as per provisions of the Drugs (Prices Control) Order, 2013 (DPCO, 2013), these ceiling prices of scheduled medicines are revised annually based on the Wholesale Price Index (WPI) (all commodities). The ceiling prices of scheduled medicines for the financial year 2024-25 were increased by 0.00551 per cent with effect from 1.4.2024, based on annual change in WPI (all commodities). NPPA also fixes the retail price of new drugs, as defined in paragraph 2(1)(u) of DPCO, 2013,” mentioned Minister of State for Chemical compounds and Fertilizers Anupriya Patel in Lok Sabha in a written reply.
The regulator additionally mentioned in a press release that “the annual change in WPI works out as (+) 1.74028 per cent during the calendar year 2024 over the corresponding period in 2023.”
What will get costlier?
In response to a Monetary Categorical report, the ceiling value of 250mg and 500mg of antibiotic azithromycin might be ₹11.87 and ₹23.98 per pill, respectively.
• The worth of dry syrups with amoxicillin and clavulanic acid is fastened at ₹2.09 per ml.
• Diclofenac (Painkiller): Most value set at ₹2.09 per pill.
• Ibuprofen (Painkiller):
– 200 mg: ₹0.72 per pill.
– 400 mg: ₹1.22 per pill.
• Diabetes medicine (Dapagliflozin + Metformin Hydrochloride + Glimepiride): Round ₹12.74 per pill.
• Acyclovir (Antiviral):
– 200 mg: ₹7.74 per pill.
– 400 mg: ₹13.90 per pill.
• Hydroxychloroquine (Antimalarial):
– 200 mg: ₹6.47 per pill.
– 400 mg: ₹14.04 per pill.
Drug producers might improve the utmost retail costs of those formulations primarily based on this WPI, and no prior approval of the Centre is critical.
The NPPA, underneath the Ministry of Chemical compounds and Fertilizers, revises the costs of important medicines yearly primarily based on the Wholesale Worth Index (WPI). The regulator maintains the costs of those medicines in a class referred to as the Nationwide Listing of Important Medicines (NLEM).